Liquidia

Greenhaven Road Capital reported an approximate 11% net return in Q2 2026 and said it will lower portfolio concentration, increase positions with near-term catalysts and take a more proactive approach to profit-taking. The firm emphasized continued focus on high-quality businesses and research that challenges consensus as several large holdings face near-term events. Greenhaven noted it sold a portion of its Liquidia position after a >30% pre-verdict rise, realizing a short-term gain, and will reassess the investment following the patent dispute outcome. » More on finance.yahoo.com

The stock of Liquidia Technologies rose 2.7% in premarket trading after the company announced its Q2 2026 results before the open and a management webcast at 8:30 a.m. ET. Analyst consensus expects about $165 million in revenue and $0.70 EPS, supported by a history of positive earnings surprises. Strong commercialization of YUTREPIA (over 4,500 prescriptions, about 3,750 treatment starts, conversion rate ≥85%) and recent price-target increases (including H.C. Wainwright $130, BTIG $109) are driving positive sentiment; the stock has gained about 105% since the end of March. » More on de.investing.com

Liquidia uses the PRINT platform to convert treprostinil into the high‑dose dry powder YUTREPIA, simplifying treatment for pulmonary hypertension. With YUTREPIA's market launch, the company has shifted from loss‑making research to a profitable specialty pharma group generating hundreds of millions in revenue. Liquidia is expanding into the PH‑ILD market, conducting studies for new patient groups and further developing the formulation L606. » More on finanzen.net